Skip to content

Fluoroscopic Guided Epidural Steroid Injection for Low Back Pain

Fluoroscopic Guided Lumbar Transforaminal or Parasagittal Interlaminar Epidural Steroid Injection for Low Back Pain With Radiculopathy : A Prospective, Randomized, Double-Blind, Active Comparator Trial

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/08/002938
Enrollment
56
Registered
2012-08-30
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- chronic low back pain with radicular pain showing than 50 on VAS

Interventions

Intervention1: Fluoroscopic Guided lumbar Transforaminal Epidural Steroid Injection: Epidural injection of Methylprednisolone acetate, 1ml (40mg) mixed with 2ml of normal saline per course. Single inj

Sponsors

Post Graduate Institute of Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: chronic low back painwith with unilateral lumbosacral radicular pain of at least one month having a pain score of >50%, as assessed by visual analog scale (VAS,0-100 points)

Exclusion criteria

Exclusion criteria: Patients were excluded if they had any clinically significant or unstable medical or psychiatric illnesses, history of previous surgery on the lumbar spine and spinal canal stenosis, unstable neurological deficits and cauda equine syndrome. Those who have received lumbar epidural steroids injections in the past, allergic to corticosteroids, taking anticoagulants or bleeding diathesis or altered coagulation, taking systematic corticosteroids, pregnant and lactating women patients or those being treated with any investigational drug within the last 30 days were excluded from the study

Design outcomes

Primary

MeasureTime frame
pain relief as assessed by VASTimepoint: 0.5, 1, 2, 3, 4, 5 and 6 months post-intervention

Secondary

MeasureTime frame
functional assessment using modified ODQ ,treatment emergent adverse drug reactionsTimepoint: 0.5, 1, 2, 3, 4, 5 and 6 months post-intervention

Countries

India

Contacts

Public ContactDr Babita Ghai

Post Graduate Institute of Medical Education and Research, Sector-12,Chandigarh, India-160012

ghaibabita@hotmail.com0991420-9533

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 7, 2026